Related Experiment Video
Updated: Jun 3, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Expression and Characterization of the HCV NS2 Protease
1Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO.
Abstract:
Heterologous expression systems have been widely used to study hepatitis C virus (HCV) proteins in lieu of an efficient method for establishing HCV infections in cell culture. Studies of HCV polyprotein processing in both mammalian-cell-based and cell-free expression systems have shown that host signalase is responsible for cleavages between the structural proteins and at the N-terminus of NS2 (1-4), whereas a chymotrypsin-like serine protease located in the N-terminal region of NS3 is responsible for most cleavages between the nonstructural proteins, including the 3/4A, 4A/4B, 4B/5A, and 5A/5B sites (5-10). However, two observations indicated that the 2/3 site is cleaved by a distinct virus-encoded protease, known as the NS2, NS2-3, or Cpro-2 protease: (1) mutation of the catalytic serine at amino acid (aa) 1165 of NS3 abolished cleavage at all sites in the nonstructural polyprotein except the 2/3 site, and (2) two mutations in NS2 located more than 30 residues from the NS2-NS3 junction abolished cleavage at the 2/3 site, but had little or no effect on downstream cleavages catalyzed by the serine protease (8,11). The minimal region required for cleavage at the 2/3 site has been mapped to aa 898 on the N-terminal side (8) and aa 1207 on the C-terminal side (11) (numbers refer to HCV 1a and 1b isolates). Although a single construct extending from aa 898 to 1207 has never been tested for proteolytic viability, cleavage with an efficiency similar to that of polypeptides containing full-length NS2 and NS3 has been demonstrated for truncated constructs extending from aa 898 to 1233 or 827 to 1207 (8,11).
Related Concept Videos
Leaky Scanning
Hepatitis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Viral Hepatitis I: Introduction

